PIQUR Therapeutics

What PIQUR Therapeutics does

PIQUR Therapeutics is a Swiss pharmaceutical company founded in 2011 and headquartered in Basel, focused on the discovery and development of anti-cancer drugs. The firm operates with 11–50 employees and maintains the leadership structure typical of a clinical-stage oncology biotech, including a Chief Scientific Officer, a Head of Drug Discovery, a Head of Preclinical Safety & Toxicology, a Head of QA, and a CFO, under the chairmanship of Richard Laube with Christian Salz serving as vice-chairman. PIQUR has been financed entirely through private venture rounds, accumulating approximately $86.9M across five disclosed events from 2010 (Venture Kick seed) through September 2017, with Versant Ventures leading the two largest disclosed rounds ($32M in 2014 and $19M in 2015).

The company does not disclose commercial products, licensed assets, or revenue in the available data, and its operating model is consistent with a pre-clinical or early-clinical pipeline company — investing raised capital into internal R&D rather than monetizing approved products. Its revenue mechanics therefore rely on continued equity financing, prospective licensing or partnership deals, or eventual product commercialization, none of which are documented in the input. PIQUR serves, in principle, oncology patients and clinicians as its eventual end market, with current counterparties being institutional investors and (implicitly) contract research and manufacturing organizations supporting its drug development activities. No pricing model, GTM motion, customer logos, geographic markets served, or partnership agreements are disclosed in the available data.

Name

PIQUR Therapeutics

Website

https://piqur.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

PIQUR Therapeutics is a Swiss pharmaceutical company founded in 2011 in Basel, focused on discovering and developing anti-cancer drugs. It operates with 11–50 employees, has raised approximately $86.9M across five venture rounds through 2017, and is backed by Versant Ventures.

Ownership category

akta.pro rank

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Core offering

PIQUR Therapeutics is a Swiss pharmaceutical company that discovers and develops anti-cancer drugs for oncology applications. The company engages in drug discovery, preclinical safety and toxicology assessment, and pharmaceutical development aimed at producing novel cancer therapeutics. Its offerings target larger pharmaceutical partners via licensing arrangements for commercialization of developed drug candidates.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights3 records

Direct peers

• MEI Pharma: Oncology-focused biotech that developed zandelisib, a PI3K delta inhibitor. Highly comparable business model and clinical-stage positioning.
• Infinity Pharmaceuticals: Clinical-stage biotech developing PI3K-targeted oncology therapeutics (eganelisib). Closely comparable as a small-cap pure-play PI3K oncology company.
• Verastem: Specialty oncology company focused on PI3K inhibitors (duvelisib/Copiktra), directly comparable in mechanism and clinical positioning to PIQUR's pipeline.

Broad incumbents

• Roche: Swiss global oncology leader with significant PI3K-related research. Provides regional/strategic context as Basel neighbor and potential acquirer of Swiss oncology biotechs.
• Novartis: Swiss global pharma with approved PI3K inhibitor alpelisib (Piqray). Competes in oncology broadly and provides a relevant benchmark for PI3K pathway commercialization in Basel.
• Bayer: Markets copanlisib (Aliqopa), a PI3K inhibitor approved for follicular lymphoma. Directly comparable given focus on PI3K inhibition in oncology.

Regional players

• Molecular Partners: Swiss clinical-stage biotech developing oncology therapeutics based on DARPin technology. Comparable as a Basel-based small-cap oncology biotech at similar stage and headcount.
• Idorsia Pharmaceuticals: Swiss clinical-stage pharma based in Basel with late-stage assets. Comparable in geography, scale, and drug-development orientation, though therapeutic focus differs.
• Basilea Pharmaceutica: Swiss-listed clinical-stage pharma with oncology and anti-infective programs. Comparable as a Basel-based small-cap listed biotech with similar scale and drug-development profile.

Emerging players

• Adlai Nortye: Clinical-stage oncology company with PI3K-alpha inhibitor buparlisib licensed from Novartis. Comparable as an emerging player in the PI3K inhibitor space pursuing strategic indications.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/piqur-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PIQUR Therapeutics